I analysen udført hos patienter med ≥4 protease- genmutationer blandt de følgende mutationer 10, 20, 24, 32, 33, 36, 46, 48, 50, 54, 63, 71, 73, 82, 84 og 90, var resultatet statistisk signifikant til fordel for lopinavir + ritonavir- armen.
In the analysis performed for patients with ≥ 4 protease gene mutations among the following set of mutations 10, 20, 24, 32, 33, 36, 46, 48, 50, 54, 63, 71, 73, 82, 84 and 90, the results significantly favoured the lopinavir + ritonavir arm.